Russell Investments Group Ltd. Has $359,000 Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Russell Investments Group Ltd. lifted its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 178.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 39,292 shares of the company’s stock after purchasing an additional 25,172 shares during the quarter. Russell Investments Group Ltd. owned 0.07% of Phathom Pharmaceuticals worth $359,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Phathom Pharmaceuticals by 355.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,626 shares of the company’s stock worth $60,000 after buying an additional 5,171 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Phathom Pharmaceuticals by 371.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,429 shares of the company’s stock worth $87,000 after purchasing an additional 6,641 shares in the last quarter. DAVENPORT & Co LLC acquired a new stake in Phathom Pharmaceuticals during the 4th quarter valued at $91,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Phathom Pharmaceuticals in the third quarter valued at $92,000. Finally, Principal Financial Group Inc. lifted its holdings in shares of Phathom Pharmaceuticals by 11.9% in the third quarter. Principal Financial Group Inc. now owns 11,801 shares of the company’s stock valued at $122,000 after purchasing an additional 1,259 shares in the last quarter. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Molly Henderson sold 3,435 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $11.10, for a total transaction of $38,128.50. Following the transaction, the chief financial officer now owns 95,263 shares in the company, valued at approximately $1,057,419.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Phathom Pharmaceuticals news, insider Terrie Curran sold 16,851 shares of the stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $9.11, for a total transaction of $153,512.61. Following the transaction, the insider now owns 410,784 shares in the company, valued at $3,742,242.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Molly Henderson sold 3,435 shares of Phathom Pharmaceuticals stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $11.10, for a total transaction of $38,128.50. Following the completion of the transaction, the chief financial officer now directly owns 95,263 shares in the company, valued at approximately $1,057,419.30. The disclosure for this sale can be found here. Insiders own 24.10% of the company’s stock.

Phathom Pharmaceuticals Price Performance

Shares of PHAT stock opened at $10.35 on Thursday. Phathom Pharmaceuticals, Inc. has a fifty-two week low of $6.07 and a fifty-two week high of $17.02. The stock’s 50-day moving average is $9.98 and its two-hundred day moving average is $8.80. The firm has a market cap of $605.79 million, a P/E ratio of -2.35 and a beta of 0.67.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($1.42) EPS for the quarter, beating the consensus estimate of ($1.43) by $0.01. The firm had revenue of $1.91 million during the quarter, compared to the consensus estimate of $2.76 million. As a group, research analysts expect that Phathom Pharmaceuticals, Inc. will post -6.61 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on PHAT. Needham & Company LLC reissued a “buy” rating and set a $26.00 price target on shares of Phathom Pharmaceuticals in a research report on Friday, May 17th. Stifel Nicolaus assumed coverage on Phathom Pharmaceuticals in a report on Friday, May 3rd. They issued a “buy” rating and a $24.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Friday, May 10th.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.